Capricor Therapeutics Inc Quick Ratio (CAPR) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Capricor Therapeutics inc   (NASDAQ: CAPR)

Capricor Therapeutics Inc 's Quick Ratio

CAPR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2026, Quick Ratio deteriorated to 8.28 above company average Quick Ratio.

Within Major Pharmaceutical Preparations industry 127 other companies have achieved higher Quick Ratio than Capricor Therapeutics Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 268 to 551.

Explain Quick Ratio?
How much Cash & cash equivalents CAPR´s has?
What are CAPR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CAPR Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1
Y / Y Current Liabilities Change 254.27 % 991.35 % 330.97 % 360.25 % 51.95 %
Y / Y Cash & cash equivalent Change 92.44 % 109.96 % 15.92 % 316.81 % 262.7 %
Quick Ratio MRQ 8.28 8.88 3.5 4.32 15.25
CAPR's Total Ranking # 551 # 268 # 755 # 535 # 165
Seq. Current Liabilities Change -6.14 % 27.31 % -0.88 % 199.08 % 189.15 %
Seq. Cash & cash equivalent Change -12.42 % 222.76 % -19.73 % -15.18 % -4.45 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 128
Healthcare Sector # 198
Overall Market # 551


Quick Ratio Statistics
High Average Low
18.91 7.3 0.75
(Jun 30 2020)   (Jun 30 2017)




Financial Statements
Capricor Therapeutics Inc 's Current Liabilities $ 34 Millions Visit CAPR's Balance sheet
Capricor Therapeutics Inc 's Cash & cash equivalent $ 279 Millions Visit CAPR's Balance sheet
Source of CAPR's Sales Visit CAPR's Sales by Geography


Cumulative Capricor Therapeutics Inc 's Quick Ratio

CAPR's Quick Ratio for the trailling 12 Months

CAPR Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth 394.59 % 358.21 % 175.09 % 87.38 % 4.32 %
Y / Y Cash & cash equivalent TTM Growth 99.16 % 123.67 % 166.98 % 266.93 % 181.9 %
Quick Ratio TTM 6.49 6.72 7.47 10.57 16.12
Total Ranking TTM # 2667 # 2327 # 2781 # 2770 # 3021
Seq. Current Liabilities TTM Growth 23.7 % 46.96 % 45.31 % 87.24 % 14.6 %
Seq. Cash & cash equivalent TTM Growth 19.56 % 32.19 % 2.69 % 22.72 % 34.28 %

Quick ratio ranking by company, industry and sector >> Back to CAPR Financial Strength Comparisons >> Go to Compare CAPR Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q1 2026 to $33.64 millions, cumulative Quick Ratio decreased to 6.49 above the CAPR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 384 other companies have achieved higher Quick Ratio than Capricor Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 2327 to 2667.

Explain Quick Ratio?
How much Cash & cash equivalents CAPR´s has?
What are CAPR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 385
Healthcare Sector # 778
Within the Market # 2667


trailing twelve months Quick Ratio Statistics
High Average Low
14.75 5.27 1.11
(Sep 30 2020)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Damora Therapeutics Inc   22.38 $ 532.899  Millions$ 23.812  Millions
Edgewise Therapeutics inc   22.16 $ 499.562  Millions$ 22.543  Millions
Keros Therapeutics Inc   21.90 $ 281.497  Millions$ 12.853  Millions
Design Therapeutics Inc   21.87 $ 222.823  Millions$ 10.190  Millions
Maplight Therapeutics Inc   21.71 $ 310.113  Millions$ 14.283  Millions
Upstream Bio Inc   21.55 $ 294.579  Millions$ 13.669  Millions
Monopar Therapeutics Inc   21.38 $ 52.544  Millions$ 2.458  Millions
Shattuck Labs Inc   21.28 $ 90.419  Millions$ 4.249  Millions
Immunome Inc   21.26 $ 582.693  Millions$ 27.412  Millions
Equillium Inc   21.12 $ 61.322  Millions$ 2.904  Millions
Generate Biomedicines Inc   20.78 $ 516.641  Millions$ 24.861  Millions
Stoke Therapeutics Inc   20.32 $ 343.545  Millions$ 16.905  Millions
Liquidia Corporation  20.29 $ 222.786  Millions$ 10.981  Millions
Vyne Therapeutics Inc   20.17 $ 24.928  Millions$ 1.236  Millions
Alto Neuroscience Inc   20.11 $ 263.762  Millions$ 13.115  Millions
Evommune Inc   19.94 $ 211.464  Millions$ 10.603  Millions
Tyra Biosciences Inc   19.91 $ 383.466  Millions$ 19.256  Millions
Sagimet Biosciences inc   19.88 $ 104.539  Millions$ 5.258  Millions
Corvus Pharmaceuticals Inc   19.55 $ 236.714  Millions$ 12.110  Millions
Ligand Pharmaceuticals Incorporated  19.17 $ 779.405  Millions$ 40.667  Millions
Dyne Therapeutics Inc   18.97 $ 972.156  Millions$ 51.249  Millions
Agios Pharmaceuticals Inc   18.41 $ 737.038  Millions$ 40.040  Millions
Crinetics Pharmaceuticals Inc   18.17 $ 1,291.306  Millions$ 71.086  Millions
Relmada Therapeutics Inc  18.15 $ 233.963  Millions$ 12.892  Millions
Phio Pharmaceuticals Corp  17.93 $ 17.031  Millions$ 0.950  Millions
Amylyx Pharmaceuticals Inc   17.52 $ 279.768  Millions$ 15.966  Millions
Minerva Neurosciences Inc   17.42 $ 78.065  Millions$ 4.482  Millions
Lexicon Pharmaceuticals Inc   17.24 $ 170.658  Millions$ 9.898  Millions
Sellas Life Sciences Group Inc   16.60 $ 107.197  Millions$ 6.456  Millions
Pliant Therapeutics Inc   16.50 $ 170.892  Millions$ 10.359  Millions

Date modified: 2026-09-26T07:11:44+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.